BRAIN Biotech AG
ISIN: DE0005203947
WKN: 520394
31 October 2024 07:11PM

EQS-Adhoc: BRAIN Biotech AG signs exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology with Akribion Therapeutics GmbH for up to EUR 92.3 million milestone fees plus royalties

BRAIN Biotech AG · ISIN: DE0005203947 · EQS - adhoc news
Country: Germany · Primary market: Germany · EQS NID: 2020423

EQS-Ad-hoc: BRAIN Biotech AG / Key word(s): Contract
BRAIN Biotech AG signs exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology with Akribion Therapeutics GmbH for up to EUR 92.3 million milestone fees plus royalties

31-Oct-2024 / 19:11 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

BRAIN Biotech AG signs exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology with Akribion Therapeutics GmbH for up to EUR 92.3 million milestone fees plus royalties

Zwingenberg, Germany, 31 October 2024 – BRAIN Biotech AG (ISIN DE0005203947; “BRAIN” or “Company”) signed an exclusive technology pharma licensing agreement with Akribion Therapeutics GmbH (“Akribion”) for its genome editing uclease G-dase E®. In exchange for granting exclusivity for pharma applications to Akribion, BRAIN can receive up to EUR 92.3 million R&D and commercial milestone fees. In addition, the company will be entitled to royalties on net sales. The payment structure is based on clinical development progress and market success of Akribion. Akribion is independently owned from the Company and seed financed by venture capital. Non-Pharma related proprietary CRISPR rights remain with BRAIN for commercialization in its core business.

This transaction remains subject to customary closing conditions.

 

Notifying person:

Martina Schuster

BRAIN Biotech AG

– Investor Relations –

Darmstädter Str. 34-36

64673 Zwingenberg

Deutschland

www.brain-biotech.com

Investor Relations Office

Tel.: +49-(0)-6251-9331-0

Fax: +49-(0)-6251-9331-11

E-Mail: ir@brain-biotech.com

IMPORTANT NOTICE

This announcement may not be published, distributed or released in the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia), Australia, Canada, Japan or any other jurisdiction in which the publication, distribution or release would be unlawful. This announcement does not constitute an offer of securities of the company for sale or a solicitation of an offer to purchase securities of the company. There will be no public offer of securities of the Company.



End of Inside Information

31-Oct-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: BRAIN Biotech AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: ir@brain-biotech.com
Internet: www.brain-biotech.com
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2020423

 
End of Announcement EQS News Service

2020423  31-Oct-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2020423&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 27,05 38,56 38,23 38,39 45,51 55,34 65,00
EBITDA1,2 -6,55 -2,50 -3,88 -2,53 -1,31 -0,83 3,50
EBITDA-Margin3 -24,21 -6,48 -10,15 -6,59 -2,88 -1,50 5,39
EBIT1,4 -9,57 -7,20 -8,23 -6,55 -5,65 -5,48 0,00
EBIT-Margin5 -35,38 -18,67 -21,53 -17,06 -12,42 -9,90 0,00
Net Profit (Loss)1 -8,37 -11,12 -9,02 -4,68 -6,34 -8,11 -4,00
Net-Margin6 -30,94 -28,84 -23,59 -12,19 -13,93 -14,66 -6,15
Cashflow1,7 -5,42 -3,38 -4,77 -3,10 -1,49 -4,22 -1,50
Earnings per share8 -0,45 -0,61 -0,52 -0,25 -0,30 -0,38 -0,18
Dividend per share8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: Baker Tilly

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
BRAIN Biotech
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
520394 DE0005203947 AG 75,81 Mio € 09.02.2016 Halten 8FXCPJH6+57
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
34,70 0,00 0,00 -7,54 3,48 -17,97 1,37
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,00 0,00 0,00 0,00%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
18.03.2025 26.02.2025 28.05.2024 29.08.2024 15.01.2025
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
-1,70%
3,47 €
ATH 27,75 €
+17,47% +32,14% -5,19% -1,70% -61,44%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL